Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Clay Thorp sold 24,500 shares of the firm’s stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $7.52, for a total transaction of $184,240.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Clay Thorp also recently made the following trade(s):

  • On Thursday, September 14th, Clay Thorp sold 6,000 shares of Clearside Biomedical stock. The shares were sold at an average price of $7.52, for a total transaction of $45,120.00.
  • On Wednesday, September 13th, Clay Thorp sold 8,500 shares of Clearside Biomedical stock. The shares were sold at an average price of $7.49, for a total transaction of $63,665.00.
  • On Tuesday, August 8th, Clay Thorp sold 5,000 shares of Clearside Biomedical stock. The shares were sold at an average price of $7.98, for a total transaction of $39,900.00.
  • On Monday, August 7th, Clay Thorp sold 4,500 shares of Clearside Biomedical stock. The shares were sold at an average price of $8.02, for a total transaction of $36,090.00.
  • On Wednesday, August 9th, Clay Thorp sold 24,500 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.57, for a total transaction of $185,465.00.

Clearside Biomedical, Inc. (CLSD) traded up 0.80% during mid-day trading on Friday, reaching $7.60. 224,557 shares of the company traded hands. The stock’s market capitalization is $192.55 million. Clearside Biomedical, Inc. has a 12-month low of $6.50 and a 12-month high of $25.08. The company’s 50-day moving average is $7.70 and its 200-day moving average is $8.08.

Clearside Biomedical (NASDAQ:CLSD) last issued its quarterly earnings results on Wednesday, August 9th. The company reported ($0.54) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by ($0.13). The firm had revenue of $0.13 million during the quarter. Clearside Biomedical had a negative return on equity of 65.78% and a negative net margin of 27,225.52%. Equities analysts predict that Clearside Biomedical, Inc. will post ($2.10) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Clearside Biomedical, Inc. (CLSD) Director Clay Thorp Sells 24,500 Shares” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/09/15/clearside-biomedical-inc-clsd-director-clay-thorp-sells-24500-shares.html.

CLSD has been the subject of several analyst reports. Zacks Investment Research lowered shares of Clearside Biomedical from a “buy” rating to a “hold” rating in a report on Monday, July 17th. JMP Securities initiated coverage on shares of Clearside Biomedical in a report on Thursday, May 25th. They set an “outperform” rating and a $21.00 price target for the company. ValuEngine upgraded shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a report on Saturday, June 24th. Cowen and Company restated a “buy” rating on shares of Clearside Biomedical in a report on Thursday, June 8th. Finally, TheStreet lowered shares of Clearside Biomedical from a “c-” rating to a “d” rating in a report on Friday, August 11th. Two analysts have rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Clearside Biomedical currently has a consensus rating of “Buy” and a consensus price target of $19.00.

A number of hedge funds have recently modified their holdings of CLSD. Nationwide Fund Advisors grew its stake in Clearside Biomedical by 118.3% in the second quarter. Nationwide Fund Advisors now owns 11,703 shares of the company’s stock worth $107,000 after purchasing an additional 6,343 shares during the period. Citadel Advisors LLC purchased a new stake in Clearside Biomedical in the second quarter worth $117,000. Parametric Portfolio Associates LLC purchased a new stake in Clearside Biomedical in the second quarter worth $122,000. Wells Fargo & Company MN grew its stake in Clearside Biomedical by 325.0% in the first quarter. Wells Fargo & Company MN now owns 16,739 shares of the company’s stock worth $133,000 after purchasing an additional 12,800 shares during the period. Finally, ProShare Advisors LLC grew its stake in Clearside Biomedical by 4.0% in the second quarter. ProShare Advisors LLC now owns 14,814 shares of the company’s stock worth $135,000 after purchasing an additional 563 shares during the period. 52.45% of the stock is currently owned by institutional investors.

About Clearside Biomedical

Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.

Insider Buying and Selling by Quarter for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.